PharmaPoint: Systemic Lupus Erythematosus and Lupus Nephritis

Systemic lupus erythematosus (SLE) is a systemic inflammatory autoimmune disease that can affect any organ or tissue and is the prototypic autoimmune disease. While SLE can affect multiple major organ systems in the body, one of its most severe manifestations includes renal (kidney) involvement, known as lupus nephritis (LN). The term LN refers to SLE patients with glomerulonephritis, and when the term LN is used, glomerular tissue injury in the kidneys is always involved. Renal injury without any glomerular involvement is classified as nephritis in a patient with SLE.

GlobalData estimates that the growth in the UK SLE and LN therapeutics will be driven by a higher uptake of existing biologic drugs, the introduction of new biologics and increasing prevalent cases of SLE and LN.

Scope

* Overview of SLE-LN including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
* Detailed information on the key drugs in UK including product description, safety and efficacy profiles as well as a SWOT analysis.
* Sales forecast for the top drugs in UK from 2012-2022.
* Analysis of the impact of key events as well the drivers and restraints affecting UK SLE-LN market.

Full Report Details at
- http://www.fastmr.com/prod/752899_pharmapoint_systemic_lupus_erythematosus_and.aspx?afid=303

Reasons to Get this Report

* Understand and capitalize by identifying products that are most likely to ensure a robust return
* Stay ahead of the competition by understanding the changing competitive landscape for SLE-LN
* Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
* Make more informed business decisions from insightful and in-depth analysis of drug performance
* Obtain sales forecast for drugs from 2012-2022 in UK

About Fast Market Research

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

You may also be interested in these related reports:

- PharmaPoint: Systemic Lupus Erythematosus and Lupus Nephritis - Japan Drug Forecast and Market Analysis to 2022
- PharmaPoint: Systemic Lupus Erythematosus and Lupus Nephritis - Spain Drug Forecast and Market Analysis to 2022
- PharmaPoint: Systemic Lupus Erythematosus and Lupus Nephritis - Italy Drug Forecast and Market Analysis to 2022
- PharmaPoint: Systemic Lupus Erythematosus and Lupus Nephritis - Germany Drug Forecast and Market Analysis to 2022
- PharmaPoint: Systemic Lupus Erythematosus and Lupus Nephritis - US Drug Forecast and Market Analysis to 2022